You searched for Small cell lung cancer

Living Room Show Notes: Small Cell Lung Cancer Treatment Landscape

Bethany Johnson (GO2 for Lung Cancer)2024-04-22T09:20:50-05:00April 22nd, 2024|Hot Topics, Newsletter Articles, Your Community|

Treatment options for people diagnosed or living with small cell lung cancer (SCLC) are constantly improving and expanding. In fact, there are more drugs in development right now than were developed in total over the last 50 years. Investments in SCLC are finally paying off, as new therapies represent hope for people living with the disease. Dr. Jared Weiss from the University of North Caroline joined GO2’s March 2024 Lung Cancer Living Room to share the breadth of currently approved [...]

0

FDA Approves Alecensa (alectinib) Following Tumor Resection for People with Early-Stage, ALK-Positive Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2024-04-19T11:06:35-05:00April 19th, 2024|Hot Topics, News, Science and Research|

Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung cancer (NSCLC). The approval is based on results from the ALINA study (NCT03456076). Participants with stage 1B (IB) to 3A (IIIA), ALK-positive NSCLC received 600 mg of Alecensa (alectinib) twice daily after surgery to remove the cancer. People treated with Alecensa [...]

0

FDA Approves Rybrevant (amivantamab-vmjw) for Non-small Cell Lung Cancer with EGFR-Exon 20 Mutation

Bethany Johnson (GO2 for Lung Cancer)2024-03-04T10:33:49-06:00March 4th, 2024|Hot Topics, News|

On March 1, 2024, the U.S. Food and Drug Administration (FDA) approved the drug Rybrevant (amivantamab-vmjw) to be given in combination with carboplatin and pemetrexed in the first lining setting for people with metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 mutation. They also announced traditional approval for Rybrevant (amivantamab-vmjw) to be given to people with metastatic non-small cell lung cancer (NSCLC) who are positive for an EGFR exon 20 mutation after they have experienced progression or recurrence [...]

0

FDA Approves Tepmetko (tepotinib) for People with Metastatic Non-Small Cell Lung Cancer with MET-Exon 14 Mutation

Bethany Johnson (GO2 for Lung Cancer)2024-02-26T16:07:12-06:00February 16th, 2024|Hot Topics, News|

On Feb. 15, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval of Tepmetko (tepotinib) for people living with metastatic non-small cell lung cancer (NSCLC) with a MET-Exon 14 mutation. Tepmetko (tepotinib) initially received accelerated approval in 2021 based on initial results from the VISION study, which evaluated the use of Tepmetko (tepotinib) in people with metastatic NSCLC with a MET-Exon 14 skipping mutation. The new approval is based on the inclusion of an additional cohort of study [...]

0

Lung Cancer Living Room: Small Cell Lung Cancer Treatment Landscape

Bethany Johnson (GO2 for Lung Cancer)2023-12-19T15:18:39-06:00December 19th, 2023|Living Room|

Find hope, knowledge, direction and connections through in-depth conversations with healthcare experts, people with lung cancer and caregivers. Learn more about the Living Room and plan to join us on YouTube Live. If attending in-person, please arrive by 5 pm PT.

0

FDA Approves Augtyro (repotrectinib) for People with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-11-16T13:48:05-06:00November 16th, 2023|Hot Topics, Science and Research|

On Nov. 16, 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for people living with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a ROS1 gene mutation. The approval was based on results from the TRIDENT-1 study, which evaluated the use of Augtyro (repotrectinib) as a first- or second-line therapy in people with locally advanced or metastatic ROS1-positive NSCLC. People receiving Augtyro (repotrectinib) for first-line treatment showed a significant response rate and a prolonged duration [...]

0

ASCO Issues New Recommendation Cosela (Trilaciclib) in Update to its Treatment Guidelines for Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-10-20T12:24:54-05:00October 20th, 2023|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On October 11, 2023, the American Society of Clinical Oncology (ASCO) recommended an update to its treatment guidelines for small cell lung cancer (SCLC). Cosela (trilaciclib) has been recommended as a myeloid supportive agent for individuals with extensive-stage SCLC who are receiving treatment with chemotherapy or chemoimmunotherapy. Myelosuppression or bone marrow suppression (when bone marrow does not make enough blood cells or platelets), is a common side effect for individuals receiving chemotherapy and increases the risk of blood disorders such as [...]

0

FDA Approves New Treatment Regimen for Individuals Receiving Keytruda (pembrolizumab) for Resectable Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-10-18T11:45:37-05:00October 18th, 2023|Hot Topics, News, Science and Research|

On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical trial that assessed a new treatment plan for persons with resectable stage II (2), IIIA (3A), or IIIB (3B) NSCLC. Individuals received Keytruda (pembrolizumab) with platinum-based chemotherapy prior to surgery (neoadjuvant treatment), followed by treatment with Keytruda (pembrolizumab) alone post-surgery (adjuvant [...]

0

FDA Approves Combination Braftovi (encorafenib) and Mektovi (binimetinib) for Metastatic BRAF-Mutated Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-10-18T12:42:35-05:00October 18th, 2023|Hot Topics, News, Science and Research|

On October 11, 2023, the U.S. Food and Drug Administration (FDA) approved a combination of Braftovi (encorafenib) and Mektovi (binimetinib) for people with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. BRAF is a less common genetic mutation, affecting 1-2% of individuals diagnosed with NSCLC, and is confirmed by biomarker testing. This approval was based on results from the PHAROS (NCT03915951) clinical trial, where individuals with a BRAF V600E mutation in NSCLC treated with Braftovi (encorafenib) plus [...]

0

Finding Strength After a Small Cell Lung Cancer Diagnosis: Bob’s Story

Bethany Johnson (GO2 for Lung Cancer)2023-10-05T15:35:59-05:00October 3rd, 2023|Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Stories of Hope, Your Community|

After spending over 20 years in the hospitality field, Bob Iles changed careers and joined the stock brokerage industry before retiring almost six years ago. He and his husband live in Palm Springs, CA, where he enjoys swimming in his lap pool, hiking, biking, volunteering for environmental and LGBTQ+ causes, and working with those facing cancer. My diagnosis and treatment In November 2019, I developed a concerning cough that led me to make an appointment with my doctor. After imaging [...]

0

Search results for "Small cell lung cancer".